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Summary For most dry powder inhalers (DPIs) a defined minimal inspiratory flow
must be achieved immediately after the start of the inspiration procedure, to avoid
insufficient deposition in the lung and excessive drug deposition in the patient’s
mouth and/or oropharynx. The Novolizers (VIATRIS GmbH & Co. KG, Frankfurt,
Germany) provides a combination of technical features that ensure that every
inhalation manoeuvre is performed with adequate inspiratory and sufficient drug
particles are delivered to the patient’s lung. One of these technical features is an
inspiratory flow rate threshold triggering feedback mechanisms to the patient which
confirm that an adequate inspiratory flow rate (minimum 35–50 l/min) has been
achieved. Correct inhalation manoeuvre is confirmed to the patient by optical,
acoustic and taste feedback which is likely to improve patient compliance. The
Novolizers also delivers a high-quality aerosol (high fine particle fraction
representing the proportion of respirable particles), provides a refillable cartridge
system, an accurate dose counter, a low intrinsic resistance, and enables reliable
and consistent dose delivery. The Novolizers is at the cutting edge of inhalation
technology and represents a major step forward in DPI design.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is a disease with increasing prevalence
around the world, particularly among children.
Asthma symptoms remain poorly controlled despite
the availability of inhaled corticosteroids and b2-
adrenergic agonists as well as the widespread
dissemination of international asthma management
guidelines.1 One reason why asthma remains poorly
controlled is the improper use of pressurised
metered-dose inhalers (pMDIs). Giraud and Roche2
assessed asthma control and pMDI technique in
4078 corticosteroid-treated patients attending
general practice. They showed that the pMDI was
misused by 71% of patients of which 47% was due to
poor co-ordination. Asthma was less stable among
pMDI misusers than in good users (Po0:001). In
addition, among misusers, asthma was less stable in
poor co-ordinators (Fig. 1). This study highlighted
the importance of evaluating inhalation technique
and providing appropriate education to all pa-
tients.
From a pharmaceutical perspective, an ‘ideal’
inhaler would have the following characteristics:
ease of manufacture; no propellant (i.e. environ-
mentally friendly); uniform dosing throughout
inhaler life; low potential for contamination and
long shelf life. However, these ideal characteristics
are very much device-driven, rather than patient-
focused. Perhaps, the most important character-
istic from a patient and physician point of view is
successful delivery of the therapeutic agent to
lungs.
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The Novolizers
The Novolizers is a new dry powder inhaler (DPI),
which is breath activated, precluding the need for
patients to co-ordinate actuation with inhalation. It
has several innovative features which confer
advantages over MDIs and other DPIs currently on
the market, and incorporates several of the
characteristics sought in the ‘ideal’ inhaler.
Device characteristics
Patients are often unsure as to whether or not they
actually inhaled medication into their lungs. With
the Novolizers, this element of uncertainty is
removed. A novel feature of the Novolizers is an
inspiratory flow rate threshold triggering a multiple
feedback mechanism to the patient every time a
defined minimum inspiratory flow rate (minimum
35–50 l/min) has been achieved.3 This makes the
Novolizers an easy to use device for inhalation
therapy because it is forgiving of poor patient
technique. The described mechanisms are essential
contributors which ensure efficient drug delivery to
the lungs. The multiple feedback mechanism of the
Novolizers confirm every correct inhalation man-
oeuvre (Fig. 2) by optical, acoustic and taste
feedback. Overcoming the minimum inspiratory
flow threshold of minimum 35–50 l/min triggers a
colour change in the lower window which switches
from green to red. At the same time, a clear
acoustic signal, a ‘click’ tone is released. In
parallel, reset of the dose counter system is
triggered. As the drug carrier particles are lactose,
a sweet taste in the patient’s mouth confirms that
the powder has been released from the inhaler.
Compared to other DPIs, the Novolizers is
characterised by low to medium airflow resistance
and a smooth increase of pressure drop at higher
flow rates during inhalation (Fig. 3). This makes it
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Figure 1 Percentage of corticosteroid-treated patients
attending general practice who had unstable asthma;
influence of pMDI technique on asthma control (&) good
users; ( ) mis-users, good co-ordinators; (\) mis-users,
poor co-ordinators. Reprinted with permission from
Giraud and Roche. Misuse of corticosteroid metered-dose
inhaler is associated with decreased asthma stability. Eur
Respir J 2002;19:246–51.
Figure 2 Inhalation procedure and device characteristics of the Novolizers for precise and consistent dose delivery
and deposition of therapeutic agent into the lungs.
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easier for the patient to use the device for
adequate drug deposition. The respirable particle
formation and flow is supported by a cyclone in the
mouthpiece (Fig. 2). The cyclone enables the
lamination of the flow in order to support effective
particle desagglomeration and the particle flow
into the lungs and to reduce deposition in the
mouth and/or oropharynx due to local turbulence.4
Finally, the powder cartridge is replaceable and the
shelf life of the device is 1 year.
Drug deposition and delivery characteristics
The Novolizers has one of the highest lung-
deposition values obtained for DPIs, e.g. averaging
32.1% of the dose at an inspiratory flow rate of 99 l/
min.5 At similar inspiratory flow rates of 54 and
58 l/min, respectively, the Novolizers achieved
similar deposition of budesonide in the lungs of
healthy volunteers as the Turbuhalers (AstraZene-
ca, Lund, Sweden), but showed significantly more
lung deposition when both devices were used with
maximum inspiratory effort, possibly because the
lower intrinsic resistance of the Novolizers allowed
higher inspiratory flow rates to be achieved.5 The
Novolizers delivered a precise and consistent
dosage over the cartridge lifetime independent of
temperature and humidity with minimal dosage
variability between actuations.4 This is not the case
for the Turbuhalers, where under conditions of high
humidity, the amount of drug released from the
device is reduced within 2 h (by approximately 35%)
and this reduction in dose lasts for up to 4 days
(Fig. 4).6 Compared to other devices on the market,
the Novolizers exhibits excellent emptying cap-
ability of the metered dose. It is functionally
reliable and hygienic in ‘real life’ situations.7,8
With DPIs, the flow rate markedly influences the
disagglomeration process and hence the delivery of
the powder particles to the lungs. This flow
dependency is not so apparent with the Novolizers
(Fig. 5).3,4 However, with the Turbuhalers, the
particle size of released powder is markedly
affected by patients’ inspiratory flow profile.9
Efficacy and handling
Efficacy, safety and tolerability of the salbutamol
Novolizers and the budesonide Novolizers have
been compared with those of inhalation devices for
the delivery of salbutamol (Sultanols) in patients
with chronic obstructive pulmonary disease10 and
for the administration of budesonide (Pulmicorts
Turbuhalers) in patients with asthma.10 The treat-
ments were therapeutically equivalent in terms of
improvement in lung function and other measures
of efficacy, safety and tolerability. In addition, the
Novolizers was accepted very well by patients. The
majority of patients who used the device in the
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Figure 4 Influence of 70% humidity on the released dose
of terbutaline from the Turbuhalers. Reprinted with
permission from Meakin et al. Effect of exposure to
humidity on terbutaline delivery from Turbuhaler dry
powder inhalation devices. Eur Respir J 1993;6:760–1.
Figure 3 Intrinsic resistance of the Novolizers com-
pared with other DPIs.
Figure 5 Amount of powder (budesonideþ lactose
carrier) emitted from the Novolizers at varying flow
rates.
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study stated that they would use it in the future.
Themultiple feedbackmechanism of the Novolizers
guides patients through the inhalation procedure
making it easy for them to learn and remember.
Most patients can learn to use the Novolizers
correctly in less than 5min. This is important for
physicians in general practice, where time is
limited. Finally, due to its low intrinsic resistance,
the Novolizers is ideal for children, elderly
patients, or those with severe obstructive lung
disease. Leupold and colleagues11 showed that,
children with mild-to-moderate persistent asthma
could correctly use the Novolizers and could easily
generate the trigger inspiratory flow rate threshold
required to deposit sufficient therapeutic agent
into the lung.
Cost effectiveness
Between 82% and 91% of patients do not use their
inhalers properly.12,13 This means that, although
MDIs appear to be cheap, they are not very cost
effective. The Novolizers may be considered cost
effective for the following reasons: the inhaler
device is robust and can be used every day several
times for up to 1 year before it needs to be
replaced. The Novolizers is refillable. The drug
cartridges are replaceable, thus reducing both cost
and waste. Finally, the most expensive inhaler is
one that the patient cannot use correctly leading to
deposition of the drug in the mouth and/or
oropharynx resulting in a corresponding reduction
of therapeutic efficacy of the drug. The technical
features around the inspiratory flow rate threshold
of the Novolizers mean that a patient receiving
optical, acoustic and sensory feedback by taste in
combination could almost not avoid adequate drug
deposition in the lungs. In case the patient does not
receive this feedback, he/she is informed that
inhalation was not correct and needs to be
repeated. With the Novolizers, the drug is con-
sistently deposited to the lungs, the site where it is
needed.
Patient compliance
Up to 50% of asthma medications are not used as
prescribed.14,15 Failure to comply with therapy is
likely to have a considerable impact on asthma-
related morbidity and mortality. The Novolizers
has several features which are likely to improve
patient compliance. The dose counter reset only
occurs upon overcoming of the inspiratory flow rate
threshold. This may improve compliance as it
positively reinforces in the patient’s mind that
inhalation manoeuvre was correct. Also, the health
care professional can follow up on doses taken and
assess compliance with therapy. Compliance may
be improved because the Novolizers is easy to use.
This is due to its low intrinsic airflow resistance and
the fact that patients are guided through the
inhalation procedure by the multiple feedback
mechanism. The multiple feedback gives the
patient clear signals that the defined minimum
inspiratory flow for delivery of sufficient medica-
tion to the lungs has been achieved (or overcome).
The inhalation procedure for the Novolizers is easy
to teach because the feedback mechanisms lead
the patient through the process and physicians
easily recognise if the patient has learned the
technique or not. In addition, study results suggest
that patients are satisfied with the use of the
Novolizers.10 The more satisfied a patient is with
an inhalation device the more likely he/she is to
use it. Finally, the Novolizers is a pocket-sized
inhalation device which is easy to carry. It has been
designed so that patients can easily carry it
wherever they go and take their medication when
needed.
Conclusions
The Novolizers presents several of the character-
istics sought in an ‘ideal’ inhaler. It contains an
inspiratory flow rate threshold linked with a multi-
ple feedback mechanism confirming correct inhala-
tion manoeuvre, indicating that essential
requirements for deposition of the therapeutic
agent in the bronchial tree have been met. The
Novolizers presents one of the highest lung
deposition values obtained for DPIs. Evaluation of
the Novolizers in randomised, controlled clinical
studies showed therapeutic equivalence to estab-
lished treatments of chronic obstructive pulmonary
disease and asthma. The Novolizers has an
accurate and robust dose counter which is based
on a reset mechanism linked to correct inhalation.
The low intrinsic airflow resistance of theNovolizers
means that it is easy to inhale through and suitable
for patients with low inspiratory flow (e.g. chil-
dren, elderly patients, patients with severe ob-
structive lung disease). The combination of these
factors is likely to improve patient compliance. The
Novolizers shows an excellent metered vs. deliv-
ered dose ratio, releases a high-quality aerosol, is
functionally reliable and hygienic in ‘real life’
situations, is environmentally friendly (does not
contain propellants) and is cost effective by virtue
of its reusability and replaceable powder car-
tridges. The Novolizers is an innovative device
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which combines simplicity of use with effective
performance.
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